Takeda Pharmaceutical's IFRS net income for fiscal year 2021 was JP¥230.166 billion, down 38.8% from JP¥376.171 billion in the previous year. Revenues rose 11.6% to JP¥3.569 trillion from JP¥3.198 trillion a year earlier.

Takeda received approval from the Japanese Ministry of Health to manufacture and sell the Covid-19 vaccine Nuvaxovid. Novavax had previously licensed and transferred its production technology so that Takeda could develop and produce the vaccine at its Hikari facility. The company will begin producing the doses purchased by the Japanese government in the near...

Committee of the Japanese Ministry of Health has recommended approval of Novavax's COVID-19 vaccine. Once fully approved, the national government will purchase 150 million doses of the drug, which will be produced domestically by Takeda Pharmaceutical.

Takeda Pharmaceutical's IFRS net income for 9 months of fiscal year 2021 was JP¥241.541 billion, up 34.9% from JP¥179.027 billion in the previous year. Revenue rose 11% to JP¥2.696 trillion compared to JP¥2.428 trillion a year earlier.